According to the latest market study released by Technaviothe global cancer pain therapeutics market is set to post a CAGR of more than 9% by 2019.
This research report titled global cancer pain therapeutics market 2015-2019 provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecast for various market segments and all geographical regions.
Imran Mushtaq, Technavio's lead research analyst, states, "Cancer pain can be acute or chronic, depending on its stages and types. It is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years."
Request sample report: http://goo.gl/KsdfNS
Drug class segmentation of the global cancer pain therapeutics market
Technavio's market research analyst segments the cancer pain therapeutics market into three different class of drugs:
- Opioids
- Non-steroidal anti-inflammatory drugs
- Others
Opioids segment
The research study explains that opioid analgesics bind to opioid receptors located in many areas of the nervous system, and are involved in pain control and signaling. They are classified into delta, kappa, mu, and sigma. Opioids directly act on the central nervous system to relieve pain.
"Opioids are further classified into strong and weak opioids. Strong opioids are given in combination with morphine, oxycodone, fentanyl, hydromorphone, and methadone, whereas weak opioids are given in combination with agents such as acetaminophen, ibuprofen, and aspirin," explains Imran Mushtaq, Technavio's lead research analyst.
The report also highlights some of the approved medications for cancer pain, which include Actiq and Fentora by Teva Pharmaceuticals, Abstral and Lazanda by ProStrakan Group, Onsolis by BioDelivery Sciences, and Transtec by Grunenthal.
Non-steroidal anti-inflammatory drugs (NSAID) segment
The research study reports that non-opioid analgesics are commonly used as medications because of their efficacy, and these drugs have antipyretic, analgesic, and anti-inflammatory actions. Non-steroidal anti-inflammatory agents block the production of prostaglandins by inhibiting the cyclooxygenase enzyme, thereby reducing the pain at the site of injury. These drugs mainly act in the peripheral tissues to inhibit the formation of prostaglandins.
The non-steroidal anti-inflammatory drugs segment are further classified into COX-1 and COX-2 inhibitors. Non-steroidal anti-inflammatory drugs were mainly developed to reduce NSAID-induced gastrointestinal toxicity. Other adverse effects associated with NSAID use are platelet dysfunction, bleeding, increased thrombotic events, delayed bone healing, bronchospasm, and renal toxicity. Indomethacin, ketorolac are COX-1 inhibitors and celecoxib, etodolac, meloxicam, diclofenac, nabumetone are COX-2 inhibitors.
Others
The research report by Technavio also draws attention towards the other drug categories that contain drugs from several classes such as tricyclic antidepressants, selective serotonin reuptake inhibitors, antihistamines, anti-anxiety drugs, stimulants and amphetamines, anti-convulsants, and steroids. These therapies are generally co-administered with analgesics such as acetaminophen, nonsteroidal anti-inflammatory drugs, and opioids for treatment of cancer pain.
Browse Related Reports:
- Global Cancer Immunotherapies Market 2016-2020
- Global Cancer Monoclonal Antibodies Market 2016-2020
- Global Cervical Cancer Market 2015-2019
Purchase these three reports for the price of one by becoming a Technavio subscriber. Subscribing to Technavio's reports allows you to download any three reports per month for the price of one. Contact enquiry@technavio.com with your requirements and a link to our subscription platform.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160119005805/en/
Contacts:
Technavio Research
Jesse Maida
Media Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com